A Novel Peptide Isolated from a Phage Display Peptide Library with Trastuzumab Can Mimic Antigen Epitope of HER-2

Beihai Jiang, Wenbin Liu, Hong Qu, Meng Lin, Shumei Song, Tao Ouyang, Chengchao Shou

Journal of Biological Chemistry · 2004 · 57 citations · 15 references

DOIFull text

Open access

Concepts

Abstract

Trastuzumab, a humanized antibody to HER-2, has been shown to be effective in the treatment of breast cancer in which HER-2 overexpression and metastasis occurs. In our search for an effective mimic epitope of HER-2 binding with trastuzumab and to develop HER-2 peptide vaccine, we screened a phage display 12-mer peptide library with trastuzumab as the target. A mimetic peptide (mimotope) H98 (LLGPYELWELSH) that could specifically recognize trastuzumab was isolated. The DNA encoding peptide H98 was cloned and expressed as the fusion protein GST-H98 in Escherichia coli BL21. The purified GST-H98 could specifically bind to trastuzumab and block the binding of trastuzumab to HER-2 protein. Moreover, H98 could significantly block the function of trastuzumab inhibiting the growth of cancer cells. Mice that were immunized with GST-H98 made specific antibody to H98 as well as to HER-2. In addition, T-cell proliferation occurred in mice immunized with GST-H98. Although no sequence homology was found between H98 and HER-2, through the use of structure analysis we were able to determine that peptide H98 contributed to a conformational epitope of HER-2. Furthermore, we determined that the last two amino acids at the C terminus, and the third together with the fourth amino acid at the N terminus of peptide H98 are critical to the binding of H98 to trastuzumab. As a result, we conclude that peptide H98 has potential for being developed as a HER-2 vaccine for biotherapy of cancer with HER-2 overexpression. Trastuzumab, a humanized antibody to HER-2, has been shown to be effective in the treatment of breast cancer in which HER-2 overexpression and metastasis occurs. In our search for an effective mimic epitope of HER-2 binding with trastuzumab and to develop HER-2 peptide vaccine, we screened a phage display 12-mer peptide library with trastuzumab as the target. A mimetic peptide (mimotope) H98 (LLGPYELWELSH) that could specifically recognize trastuzumab was isolated. The DNA encoding peptide H98 was cloned and expressed as the fusion protein GST-H98 in Escherichia coli BL21. The purified GST-H98 could specifically bind to trastuzumab and block the binding of trastuzumab to HER-2 protein. Moreover, H98 could significantly block the function of trastuzumab inhibiting the growth of cancer cells. Mice that were immunized with GST-H98 made specific antibody to H98 as well as to HER-2. In addition, T-cell proliferation occurred in mice immunized with GST-H98. Although no sequence homology was found between H98 and HER-2, through the use of structure analysis we were able to determine that peptide H98 contributed to a conformational epitope of HER-2. Furthermore, we determined that the last two amino acids at the C terminus, and the third together with the fourth amino acid at the N terminus of peptide H98 are critical to the binding of H98 to trastuzumab. As a result, we conclude that peptide H98 has potential for being developed as a HER-2 vaccine for biotherapy of cancer with HER-2 overexpression. HER-2 (also known as Neu or ErbB-2) is a member of the epidermal growth factor receptor (also known as HER) family of receptor tyrosine kinase (1Yarden Y. Sliwkowski M.X. Nat. Rev. Mol. Cell. Biol. 2001; 2: 127-137Crossref PubMed Scopus (5670) Google Scholar). HER receptors are essential mediators of cell proliferation and differentiation in the developing embryo and in adult tissues (2Olayioye M.A. Neve R.M. Lane H.A. Hynes N.E. EMBO J. 2000; 19: 3159-3167Crossref PubMed Google Scholar). Overexpression of the HER-2 oncogene is a frequent molecular event in multiple human cancers, including breast, ovarian, gastric, and colorectal carcinomas (3Wang S.C. Zhang L. Hortobagyi G.N. Hung M.C. Semin. Oncol. 2001; 28: 21-29Crossref PubMed Google Scholar). In patients with breast cancer, HER-2 overexpression is an independent predictor of survival. It is associated with poor prognosis, aggressive disease, resistance to chemotherapy and hormone therapy (4Slamon D.J. Godolphin W. Jones L.A. Holt J.A. Wong S.G. Keith D.E. Levin W.J. Stuart S.G. Udove J. Ullrich A. Press M.F. Science. 1989; 244: 707-712Crossref PubMed Scopus (6289) Google Scholar, 5Slamon D.J. Clark G.M. Wong S.G. Levin W.J. Ullrich A. McGuire W.L. Science. 1987; 235: 177-182Crossref PubMed Scopus (10014) Google Scholar, 6Nicholson R.I. McClelland R.A. Gee J.M. Manning D.L. Cannon P. Robertson J.F. Ellis I.O. Blamey R.W. Breast Cancer Res. Treat. 1994; 29: 117-125Crossref PubMed Scopus (172) Google Scholar). The critical role of HER-2 in epithelial oncogenesis as well as its selective overexpression on malignant tissues makes it an ideal target for immunotherapy (7Disis M.L. Cheever M.A. Adv. Cancer Res. 1997; 71: 343-371Crossref PubMed Google Scholar). Monoclonal antibodies directed to HER-2 induce phenotypic changes in tumor cells including down-modulation of the HER2 receptor, inhibition of tumor cells growth, reversion of cytokine resistance, restoration of E-cadherin expression levels, and reduction of vascular endothelial growth factor production (8Sliwkowski M.X. Lofgren J.A. Lewis G.D. Hotaling T.E. Fendly B.M. Fox J.A. Semin. Oncol. 1999; 26: 60-70PubMed Google Scholar). The humanized anti-HER-2/neu antibody trastuzumab (Herceptin; Genentech, Inc., South San Francisco, CA) has been proven to be effective in clinical trials in patients with HER-2-associated metastatic breast cancer (9Nahta R. Hortobagyi G.N. Esteva F.J. Oncologist. 2003; 8: 5-17Crossref PubMed Scopus (103) Google Scholar), and has antitumor activities as both a single agent and in combination with chemotherapy (10Nabholtz J.M. Reese D.M. Lindsay M.A. Riva A. Clin. Breast Cancer. 2002; 3: S75-S79Abstract Full Text PDF PubMed Scopus (35) Google Scholar). The molecular mechanisms underlying these growth inhibitory effects are not entirely clear. There is some evidence that antibodies to HER-2 may antagonize the constitutive growth signaling properties of the HER-2 system, enlist immune cells to attack the tumor target, and augment chemotherapy-induced cytotoxicity (8Sliwkowski M.X. Lofgren J.A. Lewis G.D. Hotaling T.E. Fendly B.M. Fox J.A. Semin. Oncol. 1999; 26: 60-70PubMed Google Scholar). The clinical application of trastuzumab has shown efficacy. However, several important drawbacks (generation of anti-idiotypic antibodies, inadequate tissue distribution, levels necessitating multiple infusions and hence the associated cost) limit the usefulness of passive immunotherapy protocols (11Dakappagari N.K. Pyles J. Parihar R. Carson W.E. Young D.C. Kaumaya P.T. J. Immunol. 2003; 170: 4242-4253Crossref PubMed Scopus (67) Google Scholar). On the other hand, vaccination strategy is an alternative option that can elicit endogenous tumor inhibitory antibodies, stimulate immunologic memory, and accordingly provide long-term benefits to patients at lower costs. The use of a peptide or part of a protein rather than a whole protein as vaccines may circumvent tolerance against self-protein HER-2 and induce cross-reactive immunity. Although many anti-HER-2 antibodies inhibit the proliferation of cancer cells, some actively stimulate cancer growth. It is well known that different biological effects are associated with the epitope specificity of the antibodies. Isolation of epitopes recognized by trastuzumab, an anti-tumor therapeutic monoclonal antibody directed against HER-2, can be useful in the development of peptide-based vaccines that are capable of stimulating an immune response directed to tumors. The screening of phage display libraries is a powerful technique that has been used in epitope or ligand mapping studies to define peptides that bind to a given antibody or receptor molecule (12Romanov V.I. Curr. Cancer Drug Targets. 2003; 3: 119-129Crossref PubMed Scopus (33) Google Scholar, 13Liu R. Enstrom A.M. Lam K.S. Exp. Hematol. 2003; 31: 11-30Abstract Full Text Full Text PDF PubMed Scopus (67) Google Scholar, 14Yip Y.L. Ward R.L. Curr. Pharm. Biotechnol. 2002; 3: 29-43Crossref PubMed Scopus (15) Google Scholar, 15Aina O.H. Sroka T.C. Chen M.L. Lam K.S. Biopolymers. 2002; 66: 184-199Crossref PubMed Scopus (281) Google Scholar). In this study, we used a phage display 12-mer peptide library to identify peptides that bind to trastuzumab, and tested their immune and biological activity. The screening of a 12-mer peptide library displayed on M13 filamentous phages led to the isolation of peptide H98 (LLGPYELWELSH). Further investigation showed that peptide H98, mimicking the binding epitope on HER-2 for trastuzumab, specifically blocked the binding of trastuzumab to HER-2 and elicited an anti-HER-2 antibody response as well as a cellular immune response in mice. Although no sequence homology was found between the mimotope and HER-2, given the known crystal structure of the binding domain of HER-2 and trastuzumab, we found that peptide H98 contributed to a conformational epitope of HER-2. Moreover, the last two amino acids at the C terminus, and the third together with the fourth amino acid at the N terminus of H98, were critical for the binding of H98 to trastuzumab. In addition, MutN1, a mutant of H98, enhanced the binding of trastuzumab to pro-peptide. The approach of using phage display peptide libraries to reveal conformational epitopes may play an important role in research of the immune activity of the HER-2 mimotopes. And the isolated peptide could become a candidate as a vaccine for the treatment of HER-2-associated cancers. Phage Library, Bacteria, Antibodies, Expression Vector, and Cells— The Ph.D.-12 Phage Display Peptide Library Kit E8110S was purchased from New England Biolabs (Beverly, MA). The library contained 1.5 × 1013 pfu 1The abbreviations used are: pfu, plaque-forming units; LB, Luria broth; ELISA, enzyme-linked immunosorbent assay; HRP, horseradish peroxidase; MTT, thiazolyl blue (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide); DHFR, dihydrofolate reductase./ml with a complexity of 2.7 × 109 transformants. The displayed peptides were expressed at the N terminus of the pIII coat protein of the filamentous coliphage M13. The library was stored in Tris-buffered saline, pH 7.5, with 50% glycerol. Phage was propagated in Escherichia coli strain ER2738, which was provided with the kit. Antibody trastuzumab was provided by Breast Cancer Center at Beijing Cancer Hospital. Horseradish peroxidase (HRP)-conjugated anti-M13 antibody and the glutathione S-transferase (GST) gene fusion system were purchased from Amersham Biosciences. The dihydrofolate reductase (DHFR) gene fusion system was purchased from Qiagen (Valencia, CA). The human breast cancer cell line SKBR3 (American Type Culture Collection, Manassas, VA) was cultured in Dulbecco's modified Eagle's medium (Hyclone), supplemented with 10% fetal calf serum. NIH3T3-ErbB2 cell line (provided by Dr. S. L. Sun, Peking University School of Oncology) was cultured in RPMI 1640 medium (Hyclone) supplemented with 10% fetal calf serum. Bio-panning and Selection of Phage—Human normal IgG and trastuzumab were separately immobilized on protein A-agarose beads (Amersham Biosciences). Phages (1.5 × 1011 pfu) were preabsorbed on beads containing immobilized human normal IgG to remove any phages that were not specifically reactive with trastuzumab. The phages, diluted in Tris-buffered saline containing 0.1% Tween were at for with immobilized trastuzumab. The beads were with 0.1% Tween the phages that with trastuzumab and beads were by with coli The phages were purified by with and used in the of were were and to analysis by phage enzyme-linked immunosorbent and DNA in coli Phage phage were tested for with trastuzumab by A single was for in of Luria and at cells were and the containing phage was to the of a that was with trastuzumab or human normal IgG in pH and blocked with in Tris-buffered The was at for and with phages were by with anti-M13 antibody (Amersham for by and the of a peroxidase in pH containing The was with of was determined by using a DNA and Peptide phage DNA was from by as in the phage display peptide library and by the sequence of the H98 (LLGPYELWELSH) and an peptide were by Expression of Peptide and Peptide in the activity of peptide H98 and GST-H98 and fusion were the GST-H98 fusion the and the encoding the H98, with and of shown by the were by and at the and of the (Amersham Biosciences). The were used to coli cells. DNA of was by with and and by DNA sequence of these were as by J. A Scholar). of DNA from was with a DNA CA). the of GST-H98 fusion were cultured in medium with to an of at was and the were for at were by and in of saline with and were for at a the was by at for at the GST-H98 fusion protein was purified with glutathione beads to the (Amersham Biosciences). fusion the and as were at the as and of the The were used to coli cells. The fusion protein was purified to the of trastuzumab with and GST-H98 fusion protein was tested by were with or GST-H98 fusion protein in pH blocked with in The were to of trastuzumab and for at trastuzumab was using IgG antibody with as a peroxidase as of trastuzumab with fusion protein was tested by of and fusion were to and to The were with the antibody to the expression of the fusion protein. were with trastuzumab or human IgG being the were with antibody and developed with an system (Amersham Biosciences). the inhibition of trastuzumab binding to HER-2, we with NIH3T3-ErbB2 cell was by the cells in containing and or GST-H98 fusion protein in pH trastuzumab was with of H98, and NIH3T3-ErbB2 cell and for at and to the trastuzumab was by as The peptides or were tested at and was tested in The inhibition was by using the with × The was with human breast cancer cell line SKBR3 HER-2 were in at a of × at Dulbecco's modified Eagle's medium containing trastuzumab or human normal IgG with or of peptides was to the in a of were in The were at for of cells were using a thiazolyl blue cell proliferation by The proliferation inhibition was by the as normal IgG normal IgG × to mice from the Center of the were immunized with of GST-H98 or that was in the Mice were with the in were on and the third and Antibody in the of immunized mice was determined by the were with fusion protein in pH and blocked with in A of mice was to the which were for at antibody was by using IgG antibody with as the peroxidase the anti-HER-2 were with × of NIH3T3-ErbB2 and blocked with in A of mice was to the and anti-HER-2 response was by as cells from which were immunized with GST-H98 or were isolated to the on A. A.M. Cancer Immunol. 2003; PubMed Scopus Google Scholar). were with peptide H98 at different and and with The × were cultured in the and at for The of cells were by using the thiazolyl blue cell proliferation by The proliferation was by the as × was at in The was of the and of the the for binding a of and peptides were made with The and H98 peptide fusion were expressed and purified as The of trastuzumab with these fusion peptides was tested by and and of peptide H98 Peptide H98 at the N to C to or both N and C and terminus, The mutant amino acids as well as were shown in and MutN1, acid in a Phage the that bind to trastuzumab, a 12-mer phage display peptide library of 1.5 × 1011 independent phage was preabsorbed by human IgG and specifically with trastuzumab. phages were for pfu in the and to determine the of The of phages to trastuzumab was from × pfu in the to × pfu in the third of to and of of the phage trastuzumab binding activity not phage and the amino acid sequence (LLGPYELWELSH) different was two are different and no in The binding of trastuzumab to the fusion protein GST-H98 was by and this encoding the peptide H98 was expressed as a of the protein. The of the showed that trastuzumab could specifically bind to GST-H98 not to As shown in trastuzumab with the fusion protein containing the H98, no was with The of that trastuzumab could specifically bind to H98 analysis of binding of trastuzumab to fusion were as of were to and to The were with antibody to the expression of fusion peptides and with trastuzumab or human IgG Lane GST-H98 and Peptide H98 of to from the and showed that peptide H98 to the of trastuzumab. However, to that H98 the epitope of HER-2, we to that H98 blocked binding between trastuzumab and HER-2. these we used an in which antibody and or peptide were and the with HER-2. analysis that GST-H98 and peptide H98 the binding of trastuzumab to HER-2 in a protein and peptide not inhibition on their HER-2 to GST-H98 that the trastuzumab that to GST-H98 or peptide H98 was specific for HER-2, we used HER-2 to inhibit trastuzumab binding to GST-H98. was with different of HER-2. The that HER-2 significantly trastuzumab binding to GST-H98 In a inhibition on trastuzumab binding to the GST-H98 fusion protein or the inhibition as with The that peptide H98 a critical role in inhibiting trastuzumab binding to GST-H98. Peptide H98 the of on is well known to inhibit the growth of breast cancer cells through with HER-2. peptide H98 has the to block between trastuzumab and HER-2, we to peptide H98 the of trastuzumab to inhibit cell growth. As shown in the response of breast cancer cell SKBR3 to trastuzumab was significantly blocked by peptide H98 in a and the 50% block was peptide H98 was at a of an of the peptide no on cell growth Mice with GST-H98 H98 was expressed as a fusion protein and the were in mice. of mice immunized with GST-H98 antibody as well as antibody to HER-2 the The anti-HER-2 response was lower than the and the H98 response could be than the anti-HER-2 or anti-HER-2 response was in mice immunized with of mice antibody to HER-2 that could be in an not of in mice that were immunized with GST-H98 or peptide was with T-cell proliferation The of two mice were isolated for use in this T-cell proliferation was as using H98 as a The shown in that T-cell proliferation in mice immunized with GST-H98 not in mice immunized with of H98 to in peptide may the of the peptide as well as provide an of the of the binding The and showed that of GST-H98 including and peptide fusion and H98 were able to specifically bind to trastuzumab and analysis of trastuzumab binding to different peptide fusion The fusion were as of were to and to antibody trastuzumab was used separately as the antibodies, and an antibody was to the protein as Lane As shown in and of to VA) and could not bind to trastuzumab, could bind to trastuzumab. in binding that the third and fourth amino and at the N terminus were essential for the activity of peptide Moreover, of to could bind to trastuzumab, which that and at the C terminus were essential to peptide binding activity. the of to bind to trastuzumab was significantly not which that the two at the N terminus were not important for the binding activity of H98 were to an on the structure of the Further of or at the N or C terminus the of peptide H98 to bind to trastuzumab. it that the peptide be than amino acids in to the of to the structure analysis of trastuzumab binding to HER-2 or peptide H98 with the in the the amino acid of H98 at the N terminus was from to which is to and to with trastuzumab The binding analysis that the between this of H98 and trastuzumab was and to the of on peptide and we two the peptide at the N and C terminus, and found that the of peptide to trastuzumab is significantly rather than and as a is a member of the epidermal growth factor receptor The protein of a domain with two a and an tyrosine kinase domain L. Chen A. J. J. A. Ullrich A. Science. PubMed Scopus Google Scholar). HER-2 overexpression is associated with the malignant of epithelial cells. The critical role of HER-2 in epithelial oncogenesis as well as its selective overexpression on malignant tissues makes it an ideal target for cancer and cellular to HER-2 are known to in patients with HER-2 (7Disis M.L. Cheever M.A. Adv. Cancer Res. 1997; 71: 343-371Crossref PubMed Google Scholar, M.L. Chen W. R. Cheever M.A. Cancer Res. 1994; Google Scholar, M.L. R. S. Cheever M.A. J. Clin. Oncol. 1997; PubMed Scopus Google Scholar). In HER-2 vaccines were to T-cell epitope which the use on some patients of their the use of epitope peptide vaccines may immunotherapy as using whole cells, or T-cell peptide However, studies the of immune to HER-2. (11Dakappagari N.K. Pyles J. Parihar R. Carson W.E. Young D.C. Kaumaya P.T. J. Immunol. 2003; 170: 4242-4253Crossref PubMed Scopus (67) Google Scholar, N.K. Kaumaya P.T. Cancer Res. 2000; Google the epitopes from HER-2 by and used this epitope to with a T-cell epitope from fusion protein. The peptide vaccines levels of antibodies, which tumor cell growth, in (11Dakappagari N.K. Pyles J. Parihar R. Carson W.E. Young D.C. Kaumaya P.T. J. Immunol. 2003; 170: 4242-4253Crossref PubMed Scopus (67) Google Scholar, N.K. Kaumaya P.T. Cancer Res. 2000; Google Scholar). Although analysis is for it not well the of could be by which is for a to the crystal structure of trastuzumab binding with human HER-2, we a epitope peptide containing amino acids for HER-2 binding with trastuzumab, this peptide not any binding activity with trastuzumab in our not Y.L. J. S. Ward R.L. J. Immunol. 2001; PubMed Scopus Google used the HER-2 antibody as a target for screening a phage display library of HER-2 gene and isolated a peptide containing amino which elicited the immune response to HER-2 in mice. the epitope can be a or conformational epitopes to the sequence of amino acids in the in conformational epitopes sequence from protein in the structure or its associated to a single In of the that HER-2 gene libraries screening phage display peptide libraries may be a and to not epitopes conformational search for the peptides that could mimic the epitope of HER-2 and potential as a vaccine in S. A. L. J. Immunol. PubMed Scopus Google used trastuzumab as the target to the phage display peptide and candidate that could induce an antibody response to HER-2 S. A. L. J. Immunol. PubMed Scopus Google Scholar). we screened a 12-mer phage display peptide library by with the antibody trastuzumab as the target and a different peptide (LLGPYELWELSH) from In our of screening the some were to the between the peptides and the antibodies, we used of the which is to remove the the phage display library was with human of the phages from the target the was in our by coli with phages binding with trastuzumab and protein A phage were from and were by DNA the effects of phage protein in the the peptide fusion protein was The GST-H98 showed binding activity to trastuzumab, not not Further analysis that the isolated mimotope H98 not specifically the binding of trastuzumab to HER-2, blocked the function of trastuzumab in inhibiting the proliferation of cancer cells. Moreover, analysis that H98 could induce an immune response to HER-2 in that H98 is to the epitope of HER-2 that is recognized by trastuzumab. Although no sequence homology was found between the mimotope and HER-2 by sequence our that H98 a conformational structure of the HER-2. the binding structure of peptide H98 with trastuzumab, we used the and a crystal structure of human HER-2 binding with trastuzumab at A.M. D.J. 2003; PubMed Scopus Google Scholar). in was to the of H98 and trastuzumab. The between HER-2 and trastuzumab of a and an for The was by of by and the of a by by the and third were the made in a by the of and of the The crystal structure of HER-2 with trastuzumab showed that is and in to and which are amino an epitope of HER-2 in structure and were well by the sequence in peptide acids and are in as are and Moreover, could be by to with and of trastuzumab epitope structure analysis that H98 could mimic the epitope of HER-2 binding to trastuzumab in which is with our Moreover, that could with trastuzumab, we made a mutant in which the amino acid of H98 was from to The mutant H98 a binding activity to trastuzumab. identify the critical amino acids in H98 for its binding to trastuzumab, we made and of the peptide H98 The binding showed that the last two amino acids at the C terminus and the third together with the fourth amino acid at the N terminus play an important role in the binding of H98 to trastuzumab. In peptide H98, which was isolated from the phage display peptide library with trastuzumab, could mimic the epitope of HER-2 on a structure and elicit the and cellular immune to HER-2. peptide for development as a HER-2 vaccine for biotherapy of cancer that HER-2. Dr. for on the

References

15